Prilenia Therapeutics B.V., a biopharmaceutical company focused on developing novel therapeutics to treat neurodegenerative ...
Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...
Patient involvement in health policy is a patchwork across the EU. Putting the lived experience front and centre of policy-making was prioritised at a recent high-level policy event organised by the ...
Alvotech (ALVO) and Advanz Pharma announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT05, ...
Some experts argue that neural data should be subject to greater protection. View on euronews ...
The Canadian healthcare-focused royalty company said Monday that the royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals was acquired for an ...
About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised ...
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.
Chemical stability: Many medications can be sensitive to pH changes. For instance, certain antibiotics and hormones can break down and lose their effectiveness if they’re not kept in the right pH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback